|
1
|
Bray F, Ferlay J, Soerjomatarum I, Siegal
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Clancy C, Burke JP, Barry M, Kalady MF and
Calvin Coffey J: A meta-analysis to determine the effect of primary
tumour resection for stage IV colorectal cancer with unresectable
metastases on patient survival. Annals Surg Oncol. 21:3900–3908.
2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kim CW, Baek JH, Choi GS, Yu CS, Kang SB,
Park WC, Lee BH, Kim HR, Oh JH, Kim JH, et al: The role of primary
tumour resection in the colorectal cancer patients with
asymptomatic, synchronous unresectable metastasis: Study protocol
for a randomized control trial. Trials. 17(34)2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tan WJ, Patil S, Guillem JG, Paty PB,
Weiser MR, Nash GM, Smith JJ, Pappou EP, Wei IH and Garcia-Aguilar
J: Primary Tumour-related complications and salvage outcomes in
patients with metastatic rectal cancer and an untreated primary
tumour. Dis Colon Rectum. 64:45–52. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
de Mestier L, Manceau G, Neuzillet C,
Bachet JB, Spano JP, Kianmanesh R, Vaillant JC, Bouché O, Hannoun L
and Karoui M: Primary tumour resection in colorectal cancer with
unresectable synchronous metastases: A review. World J Gastrointest
Oncol. 6:156–169. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Machover D: A comprehensive review of
5-fluorouracil and leucovorin in patients with metastatic
colorectal carcinoma. Cancer. 8:1179–1187. 1997.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kurkjian C and Kummar S: Advances in the
treatment of metastatic colorectal cancer. Am J Ther. 16:412–420.
2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Leicher LW, de Graaf JC, Coers W, Tascilar
M and de Groot JWB: Tolerability of capecitabine monotherapy in
metastatic colorectal cancer: A real-world study. Drugs R D.
17:117–124. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fujita K, Kubota Y, Ishida H and Sasaki Y:
Irinotecan, a key chemotherapeutic drug for metastatic colorectal
cancer. World J Gastroenterol. 21:12234–12248. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Comella P, Casaretti R, Sandomenico C,
Avallone A and Franco L: Role of oxaliplatin in the treatment of
colorectal cancer. Ther Clin Risk Manag. 5:229–238. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fornasier G, Francescon S and Baldo P: An
update of efficacy and safety of cetuximab in metastatic colorectal
cancer: A narrative review. Adv Ther. 35:1497–1509. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Battagin F, Puccini A, Djaballah SA and
Lenz HJ: The impact of panitumumab treatment on survival and
quality of life in patients with RAS wild-type metastatic
colorectal cancer. Cancer Manag Res. 11:5911–5924. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rosen LS, Jacobs IA and Burkes RL:
Bevacizumab in colorectal cancer: Current role in treatment and the
potential of biosmiliars. Target Oncol. 12:599–610. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Verdaguer H, Tebernero J and Macarulla T:
Ramucirumab in metastatic colorectal cancer: Evidence to date and
place in therapy. Ther Adv Med Oncol. 8:230–242. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yoshihiro T, Kusaba H, Makiyama A,
Kobayashi K, Uenomachi M, Ito M, Doi Y, Mitsugi K, Aikawa T,
Takayoshi K, et al: Efficacy and safety of ramucirumab plus
modified FOLFIRI for metastatic colorectal cancer. Int J Clin
Oncol. 24:508–515. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Braun MS, Adab F, Bradley C, McAdam K,
Thomas G, Wadd NJ, Rea D, Philips R, Twelves C, Bozzino J, et al:
Modified de Gramont with oxaliplatin in the first-line treatment of
advanced colorectal cancer. Br J Cancer. 89:1155–1158.
2003.PubMed/NCBI View Article : Google Scholar
|
|
17
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 18:2938–2947. 2000.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Guo Y, Xiong BH, Zhang T, Cheng Y and Ma
L: XELOX vs. FOLFOX in metastatic colorectal cancer: An updated
meta-analysis. Cancer Invest. 34:94–104. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cassidy J, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F and
Saltz L: XELOX vs FOLFOX-4 as first-line therapy for metastatic
colorectal cancer: NO16966 updated results. Br J Cancer. 105:58–64.
2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Saltz LB, Douillard JY, Pirotta N, Alakl
M, Gruia G, Awad L, Elfring GL, Locker PK and Miller LL: Irinotecan
plus fluorouracil/leucovorin for metastatic colorectal cancer: A
new survival standard. Oncologist. 6:81–91. 2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tournigard C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Price TJ: Modified XELIRI (capecitabine
plus irinotecan) for metastatic colorectal cancer. Lancet Oncol.
19:587–589. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yaffee P, Osipov A, Tan C, Tuli R and
Hendifar A: Review of systemic therapies for locally advanced and
metastatic rectal cancer. J Gastrointest Oncol. 6:185–200.
2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Suzuki K, Takaharu K, Muto Y, Ichida K,
Fukui T, Takayama Y, Tsujinaka S, Sasaki J, Horie H, Kawamura YJ,
et al: XELIRI regimen plus continuous treatment with bevacizumab is
well-tolerated and effective in metastatic colorectal cancer
patients in a second-line setting involving the sequential
administration of XELOX and XELIRI. Mol Clin Oncol. 2:827–832.
2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kawai S, Takeshima N, Hayasaka Y, Notsu A,
Yamazaki M, Kawabata T, Yamazaki K, Mori K and Yasui H: Comparison
of irinotecan and oxaliplatin as the first-line therapies for
metastatic colorectal cancer: A meta-analysis. BMC Cancer.
21(116)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Marschner N, Arnold D, Engel E,
Hutzschenreuter U, Rauh J, Freier W, Hartmann H, Frank M and
Jänicke M: Oxaliplatin-based first-line chemotherapy is associated
with improved overall survival compared to first-line treatment
with irinotecan-based chemotherapy in patients with metastatic
colorectal cancers-Results from a prospective cohort study. Clin
Epidemiol. 7:295–303. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Colucci G, Gebbia V, Paoletti G, Giuliani
F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione
L, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in
the treatment of advanced colorectal cancer: A multicenter study of
the Gruppo Oncologico Dell'Italia meridionale. J Clin Oncol.
23:4866–4875. 2005.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Aparicio T, Desramé J, Lecomte T, Mitry E,
Belloc J, Etienney I, Montembault S, Vayre L, Locher C, Ezenfis J,
et al: Oxaliplatin- or irinotecan-based chemotherapy for metastatic
colorectal cancer in the elderly. Br J Cancer. 89:1439–1444.
2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
André T, Afchain P, Barrier A, Blanchard
P, Larsen AK, Tournigand C, Louvet C and de Gramont A: Current
status of adjuvant therapy for colon cancer. Gastrointest Cancer
Res. 1:90–97. 2007.PubMed/NCBI
|
|
31
|
Patel K, Anthoney DA, Crellin AM,
Sebag-Montefiore D, Messruther J and Seymour MT: Weekly
5-fluorouracil and leucovorin: Achieving lower toxicity with higher
dose-intensity in adjuvant chemotherapy after colorectal cancer
resection. Ann Oncol. 15:568–573. 2004.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Schippinger W, Samonigg H, Schaberl-Moser
R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG,
Jakesz R, Herbst F, et al: A prospective randomised phase III trial
of adjuvant chemotherapy with 5-fluorouracil and leucovorin in
patients with stage II colon cancer. Br J Cancer. 97:1021–1027.
2007.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Fotheringham S, Mozolowski GA, Murray EMA
and Kerr DJ: Challenges and solutions in patient treatment
strategies for stage II colon cancer. Gastroenterol Rep (Oxf).
7:151–161. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Twelves C, Wong A, Nowacki MP, Abt M,
Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J,
Georgoulias V, et al: Capecitabine as adjuvant treatment for stage
III colon cancer. N Engl J Med. 352:2696–2704. 2005.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Cassidy J, Twelves C, Van Cutsem E, Hoff
P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, et
al: First-line oral capecitabine therapy in metastatic colorectal
cancer: A favorable safety profile compared with intravenous
5-fluorouracil/leucovorin. Ann Oncol. 13:566–575. 2002.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Rizzo A, Nannini M, Astolfi A, Indio V, De
Iaco P, Perrone AM, De Leo A, Incorvaia L, Di Scioscio V and
Pantaleo MA: Impact of chemotherapy in the adjuvant setting of
early stage uterine leiomyosarcoma: A systematic review and updated
meta-analysis. Cancers (Basel). 12(1899)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Rosales J and Leong LA: Chemotherapy for
metastatic colorectal cancer. J Natl Compr Canc Netw. 3:525–529.
2005.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Mayer RJ, Van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med. 372:1909–1919.
2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Tonini G, Imperatori M, Vincenzi B, Frezza
AM and Santini D: Rechallenge therapy and treatment holiday:
Different strategies in management of metastatic colorectal cancer.
J Exp Clin Cancer Res. 32(92)2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Bekaii-Saab T, Kim R, Kim TW, O'Connor JM,
Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K,
Yoshino T and Prager GW: Third- or Later-line therapy for
metastatic colorectal cancer: Reviewing best practice. Clin
Colorectal Cancer. 18:e117–e129. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kopetz S, Grothey A, Yaeger R, Van Cutsem
E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS,
et al: Encorafenib, Binimetinib, and cetuximab in BRAF
V600E-mutated colorectal cancer. N Engl J Med. 381:1632–1643.
2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A review. JAMA.
325:669–685. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Smith KM and Desai J: Nivolumab for the
treatment of colorectal cancer. Expert Rev Anticancer Ther.
18:611–618. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus Ipilimumab
in DNA mismatch Repair-Deficient/Microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779.
2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Zheng Z, Yu T, Zhao X, Gao X, Zhao Y and
Liu G: Intratumour heterogeneity: A new perspective on colorectal
cancer research. Cancer Med. 9:7637–7645. 2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Losi L, Baisse B, Bouzourene H and
Benhattar J: Evolution of intratumoural genetic heterogeneity
during colorectal cancer progression. Carcinogenesis. 26:916–922.
2005.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Molinari C, Marisi G, Passardi A,
Matteucci L, De Maio G and Ulivi P: Heterogeneity in colorectal
cancer: A challenge for personalized medicine? Int J Mol Sci.
19(3733)2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Buikhuisen JY, Torang A and Medema JP:
Exploring and modelling colon cancer inter-tumour heterogeneity:
Opportunities and challenges. Oncogenesis. 9(66)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Del Carmen S, Sayagués JM, Bengoechea O,
Anduaga MF, Alcazar JA, Gervas R, García J, Orfao A, Bellvis LM,
Sarasquete ME and Del Mar Abad M: Spatio-temporal tumour
heterogeneity in metastatic CRC tumours: A mutational-based
approach. Oncotarget. 9:34279–34288. 2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Blank A, Roberts DE II, Dawson H, Zlobec I
and Lugli A: Tumour heterogeneity in primary colorectal cancer and
corresponding metastases. Does the apple fall far from the tree?
Front Med (Lausanne). 5(234)2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Eide PW, Moosavi SH, Eilertsen IA,
Brunsell TH, Langerud J, Berg KCG, Røsok BI, Bjørnbeth BA,
Nesbakken A, Lothe RA and Sveen A: Metastatic heterogeneity of the
consensus molecular subtypes of colorectal cancer. NPJ Genom Med.
6(59)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Hirata A, Hatano Y, Niwa M, Hara A and
Tomita H: Heterogeneity of colon cancer stem cells. Adv Exp Med
Biol. 1139:115–126. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Arakawa K, Hata K, Nozawa H, Kawai K,
Tanaka T, Nishikawa T, Sasaki K, Shuno Y, Kaneko M, Hiyoshi M, et
al: Molecular subtypes are frequently discordant between lesions in
patients with synchronous colorectal cancer: Molecular analysis of
59 patients. Anticancer Res. 39:1425–1432. 2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Li ZN, Zhao L, Yu LF and Wei MJ: BRAF and
KRAS mutations in metastatic colorectal cancer: Future perspectives
for personalized therapy. Gastroenterol Rep (Oxf). 8:192–205.
2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Christensen TD, Palshof JA, Larsen FO,
Poulsen TS, Høgdall E, Pfeiffer P, Jensen BV, Yilmaz MK and Nielsen
D: Associations between primary tumour RAS, BRAF and PIK3CA
mutation status and metastatic site in patients with
chemo-resistant metastatic colorectal cancer. Acta Oncol.
57:1057–1062. 2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Fedyanin M, Stroganova A, Senderovich A,
Dranko S, Tryakin A, Polyanskaya E, Popova A, Sekhina O, Rasulov A,
Gordeev S, et al: Factors associated with discordance of KRAS,
NRAS, BRAF, PIK3CA mutation status in the primary tumour and
metastases in patients (pts) with colorectal cancer (CRC). Annals
Oncol. 27 (Suppl 6)(VI174)2016.
|
|
60
|
Watanabe T, Kobunai T, Yamamoto Y, Matsuda
K, Ishihara S, Nozawa K, Iinuma H, Shibuya H and Eshima K:
Heterogeneity of KRAS status may explain the subset of discordant
KRAS status between primary and metastatic colorectal cancer. Dis
Colon Rectum. 54:1170–1178. 2011.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Siyar Ekinci A, Demirci U, Cakmak
Oksuzoglu B, Ozturk A, Esbah O, Ozatli T, Celik B, Budakoglu B,
Turker I, Bal O and Turan N: KRAS discordance between primary and
metastatic tumour in patients with metastatic colorectal carcinoma.
J BUON. 20:128–135. 2015.
|
|
62
|
Ardito F, Razionale F, Salvatore L, Cenci
T, Vellone M, Basso M, Panettieri E, Calegari MA, Tortora G,
Martini M and Giuliante F: Discordance of KRAS mutational status
between primary tumours and liver metastases in colorectal cancer:
Impact on long-term survival following radical resection. Cancers
(Basel). 13(2148)2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Estrella JS, Tetzlaff MT, Bassett RL Jr,
Patel KP, Williams MD, Curry JL, Rashid A, Hamilton SR and Broaddus
RR: Assessment of BRAF V600E status in colorectal carcinoma:
Tissue-specific discordances between immunohistochemistry and
sequencing. Mol Cancer Ther. 14:2887–2895. 2015.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Mas L, Bachet JB, Taly V, Bouché O, Taieb
J, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, et al: BRAF
mutation status in circulating tumour DNA from patients with
metastatic colorectal cancer: Extended mutation analysis from the
AGEO RASANC study. Cancers (Basel). 11(998)2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Bai H, Wang R, Cheng W, Shen Y, Li H, Xia
W, Ding Z and Zhang Y: Evaluation of concordance between deficient
mismatch repair and microsatellite instability testing and their
association with clinicopathological features in colorectal cancer.
Cancer Manag Res. 12:2863–2873. 2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Haraldsdottir S, Roth R, Pearlman R,
Hampel H, Arnold CA and Frankel WL: Mismatch repair deficiency
concordance between primary colorectal cancer and corresponding
metastasis. Fam Cancer. 15:253–260. 2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Vyas M, Firat C, Hechtman JF, Weiser MR,
Yaeger R, Vanderbilt C, Benhamida JK, Keshinro A, Zhang L, Ntiamoah
P, et al: Discordant DNA mismatch repair protein status between
synchronous or metachronous gastrointestinal carcinomas: Frequency,
patterns, and molecular etiologies. Fam Cancer. 20:201–213.
2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Yaeger R: Heterogeneity in microsatellite
instability in metastatic colorectal cancer: Mechanisms and
clinical implications. J Natl Compr Canc Netw. 17:1263–1264.
2019.PubMed/NCBI View Article : Google Scholar
|
|
69
|
De Smedt L, Lemahieu J, Palmans S, Govaere
O, Tousseyn T, Van Cutsem E, Prenen H, Tejpar S, Spaepen M,
Matthijs G, et al: Microsatellite instable vs stable colon
carcinomas: Analysis of tumour heterogeneity, inflammation and
angiogenesis. Br J Cancer. 113:500–509. 2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Levin-Sparenberg E, Bylsma LC, Lowe K,
Sangare L, Fryzek JP and Alexander DD: A systematic literature
review and meta-analysis describing the prevalence of KRAS, NRAS,
and BRAF Gene mutations in metastatic colorectal cancer.
Gastroenterology Res. 13:184–198. 2020.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Hu Y, Tao SY, Deng JM, Hou ZK, Liang JQ,
Huang QG, Li LH, Li HB, Chen YM, Yi H, et al: Prognostic value of
NRAS gene for survival of colorectal cancer patients: A systematic
review and meta-analysis. Asian Pac J Cancer Prev. 19:3001–3008.
2018.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Wang J, Shen J, Huang C, Cao M and Shen L:
Clinicopathological significance of BRAFV600E mutation
in colorectal cancer: An updated meta-analysis. J Cancer.
10:2332–2341. 2019.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Wensink E, Bond M, Kucukkose E, May A,
Vink G, Koopman M, Kranenburg O and Roodhart J: A review of the
sensitivity of metastatic colorectal cancer patients with deficient
mismatch repair to standard-of-care chemotherapy and monoclonal
antibodies, with recommendations for future research. Cancer Treat
Rev. 95(102174)2021.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Wheeler JM, Bodmer WF and Mortensen NJ:
DNA mismatch repair genes and colorectal cancer. Gut. 47:148–153.
2000.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Hou JT, Zhao LN, Zhang DJ, Lv DY, He WL,
Chen B, Li HB, Li PR, Chen LZ and Chen XL: Prognostic value of
mismatch repair genes for patients with colorectal cancer:
Meta-analysis. Technol Cancer Res Treat.
17(1533033818808507)2018.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Kang S, Na Y, Joung SY, Lee SI, Oh SC and
Min BW: The significance of microsatellite instability in
colorectal cancer after controlling for clinicopathological
factors. Medicine (Baltimore). 97(e0019)2018.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Nojadeh JN, Behrouz Sharif S and Sakhinia
E: Microsatellite instability in colorectal cancer. EXCLI J.
17:159–168. 2018.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Anele CC, Adegbola SO, Askari A, Rajendran
A, Clark SK, Latchford A and Faiz OD: Risk of metachronous
colorectal cancer following colectomy in Lynch syndrome: A
systematic review and meta-analysis. Colorectal Dis. 19:528–536.
2017.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Duraturo F, Liccardo R, De Rosa M and Izzo
P: Genetics, diagnosis and treatment of Lynch syndrome: Old lessons
and current challenges. Oncol Lett. 17:3048–3054. 2019.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Boland CR and Goel A: Microsatellite
instability in colorectal cancer. Gastroenterology.
138:2073–2087.e3. 2010.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Morelli MP, Overman MJ, Dasari A, Kazmi
SMA, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, et al:
Characterizing the patterns of clonal selection in circulating
tumour DNA from patients with colorectal cancer refractory to
anti-EGFR treatment. Ann Oncol. 26:731–736. 2015.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Van Emburgh BO, Sartore-Bianchi A, Di
Nicolantonio F, Siena S and Bardelli A: Acquired resistance to
EGFR-targeted therapies in colorectal cancer. Mol Oncol.
8:1084–1094. 2014.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Yachida S, Jones S, Bozic I, Antal T,
Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al:
Distant metastasis occurs late during the genetic evolution of
pancreatic cancer. Nature. 467:1114–1117. 2010.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Sottoriva A, Kang H, Ma Z, Graham TA,
Salomon MP, Zhao J, Marjoram P, Siegmund K, Press MF, Shibata D and
Curtis C: A Big Bang model of human colorectal tumour growth. Nat
Genet. 47:209–216. 2015.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Fujiyoshi K, Yamamoto G, Takahashi A, Arai
Y, Yamada M, Kakuta M, Yamaguchi K, Akagi Y, Nishimura Y, Sakamoto
H and Akagi K: High concordance rate of KRAS/BRAF mutations and
MSI-H between primary colorectal cancer and corresponding
metastases. Oncol Rep. 37:785–792. 2017.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Bhullar DS, Barriuso J, Mullamitha S,
Saunders MP, O'Dwyer ST and Aziz O: Biomarker concordance between
primary colorectal cancer and its metastases. EBioMedicine.
40:363–374. 2019.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Ruiz-Bañobre J, Kandimalla R and Goel A:
Predictive biomarkers in metastatic colorectal cancer: A systematic
review. JCO Precis Oncol. 3(PO.18.00260)2019.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Zou Y, Hu X, Zheng S, Yang A, Li X, Tang
H, Kong Y and Xie X: Discordance of immunotherapy response
predictive biomarkers between primary lesions and paired metastases
in tumours: A systematic review and meta-analysis. EBioMedicine.
63(103137)2021.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Zou SM, Li WH, Wang WM, Li WB, Shi SS,
Ying JM and Lyu N: The gene mutational discrepancies between
primary and paired metastatic colorectal carcinoma detected by
next-generation sequencing. J Cancer Res Clin Oncol. 144:2149–2159.
2018.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Guyot D'Asnières De Salins A, Tachon G,
Cohen R, Karayan-Tapon L, Junca A, Frouin E, Godet J, Evrard C,
Randrian V, Duval A, et al: Discordance between immunochemistry of
mismatch repair proteins and molecular testing of microsatellite
instability in colorectal cancer. ESMO Open.
6(100120)2021.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Mao C, Wu XY, Yang ZY, Threapleton DE,
Yuan JQ, Yu YY and Tang JL: Concordant analysis of KRAS, BRAF,
PIK3CA mutations, and PTEN expression between primary colorectal
cancer and matched metastases. Sci Rep. 5(8065)2015.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Kim KP, Kim JE, Hong YS, Ahn SM, Chun SM,
Hong SM, Jang SJ, Yu CS, Kim JC and Kim TW: Paired primary and
metastatic tumour analysis of somatic mutations in synchronous and
metachronous colorectal cancer. Cancer Res Treat. 49:161–167.
2017.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Jesinghaus M, Wolf T, Pfarr N, Muckenhuber
A, Ahadova A, Warth A, Goeppert B, Sers C, Kloor M, Endris V, et
al: Distinctive spatiotemporal stability of somatic mutations in
metastasized microsatellite-stable colorectal Cancer. Am J Surg
Pathol. 39:1140–1147. 2015.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Lee CC, Soon YY, Lum JHY, Tan CL and Tey
JCS: Frequency of discordance in programmed death-ligand 1 (PD-L1)
expression between primary tumours and paired distant metastases in
advanced cancers: A systematic review and meta-analysis. Acta
Oncol. 59:696–704. 2020.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumour heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Molinari F, Martin V, Saletti P, De Dosso
S, Spitale A, Camponovo A, Bordoni A, Crippa S, Mazzucchelli L and
Frattini M: Differing deregulation of EGFR and downstream proteins
in primary colorectal cancer and related metastatic sites may be
clinically relevant. Br J Cancer. 100:1087–1094. 2009.PubMed/NCBI View Article : Google Scholar
|
|
98
|
He Q, Xu Q, Wu W, Chen L, Sun W and Ying
J: Comparison of KRAS and PIK3CA gene status between primary
tumours and paired metastases in colorectal cancer. Onco Targets
Ther. 9:2329–2335. 2016.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Niitsu H, Hinoi T, Shimomura M, Egi H,
Hattori M, Ishizaki Y, Adachi T, Saito Y, Miguchi M, Sawada H, et
al: Up-front systemic chemotherapy is a feasible option compared to
primary tumour resection followed by chemotherapy for colorectal
cancer with unresectable synchronous metastases. World J Surg
Oncol. 13(162)2015.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Giacchetti S, Itzhaki M, Gruia G, Adam R,
Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic
F, Jasmin C, et al: Long-term survival of patients with
unresectable colorectal cancer liver metastases following
infusional chemotherapy with 5-fluorouracil, leucovorin,
oxaliplatin and surgery. Ann Oncol. 10:663–669. 1999.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Stillwell AP, Buettner PG and Ho YH:
Meta-analysis of survival of patients with stage IV colorectal
cancer managed with surgical resection versus chemotherapy alone.
World J Surg. 34:797–807. 2010.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Wang G, Wang W, Jin H, Dong H, Chen W, Li
X, Li G and Li L: The effect of primary tumour radiotherapy in
patients with Unresectable stage IV rectal or Rectosigmoid cancer:
A propensity score matching analysis for survival. Radiat Oncol.
15(126)2020.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Poultsides GA and Paty PB: Reassessing the
need for primary tumour surgery in unresectable metastatic
colorectal cancer: Overview and perspective. Ther Adv Med Oncol.
3:35–42. 2011.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Park JH, Kim TY, Lee KH, Han SW, Oh DY, Im
SA, Kang GH, Chie EK, Ha SW, Jeong SY, et al: The beneficial effect
of palliative resection in metastatic colorectal cancer. Br J
Cancer. 108:1425–1431. 2013.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Simillis C, Kalakouti E, Afxentiou T,
Kontovounisios C, Smith JJ, Cunningham D, Adamina M and Tekkis PP:
Tumour resection in patients with incurable localized or metastatic
colorectal cancer: A systematic review and meta-analysis. World J
Surg. 43:1829–1840. 2019.
|
|
106
|
Feo L, Polcino M and Nash GM: Resection of
the primary tumour in stage IV colorectal cancer: When is it
necessary? Surg Clin North Am. 97:657–669. 2017.PubMed/NCBI View Article : Google Scholar
|
|
107
|
www.beaumont.ie/media/Testing_Services_Offered1.pdf.
|
|
108
|
Radiology Assistant: RECIST 1.1-and more.
Response Evaluation Criteria In Solid Tumors. https://radiologyassistant.nl/more/recist-1-1/recist-1-1.
Accessed December 7, 2021.
|
|
109
|
Cutsem EV, Cervantes A, Nordlinger B and
Arnold D: ESMO Guidelines Working Group. Metastatic colorectal
cancer: ESMO clinical practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 25 (Suppl 3):iii1–iii9. 2014.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Chiorean EG, Nandakumar G, Fadelu T, Temin
S, Alarcon-Rozas AE, Bejarano S, Croitoru AE, Grover S, Lohar PV,
Odhiambo A, et al: Treatment of patients with late-stage colorectal
cancer: ASCO Resource-stratified guideline. JCO Glob Oncol.
6:414–438. 2020.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Muratore A, Zorzi D, Bouzari H, Amisano M,
Massucco P, Sperti E and Capussotti L: Asymptomatic colorectal
cancer with Un-Resectable liver metastases: Immediate colorectal
resection or up-front systemic chemotherapy? Ann Surg Oncol.
14:766–770. 2007.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Pędziwiatr M, Mizera M, Witowski J, Major
P, Torbicz G, Gajewska N and Budzyński A: Primary tumour resection
in stage IV unresectable colorectal cancer: What has changed? Med
Oncol. 34(188)2017.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Poultsides GA, Servais EL, Saltz LB, Patil
S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD and Paty PB:
Outcome of primary tumour in patients with synchronous stage IV
colorectal cancer receiving combination chemotherapy without
surgery as initial treatment. J Clin Oncol. 27:3379–3384.
2009.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Seo GJ, Park JW, Yoo SB, Kim SY, Choi HS,
Chang HJ, Shin A, Jeong SY, Kim DY and Oh JH: Intestinal
complications after palliative treatment for asymptomatic patients
with unresectable stage IV colorectal cancer. J Surg Oncol.
102:94–99. 2010.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Rahbari NN, Lordick F, Fink C, Bork U,
Stange A, Jäger D, Luntz SP, Englert S, Rossion I, Koch M, et al:
Resection of the primary tumour versus no resection prior to
systemic therapy in patients with colon cancer and synchronous
unresectable metastases (UICC stage IV): SYNCHRONOUS-a randomised
controlled multicentre trial (ISRCTN30964555). BMC Cancer.
12(142)2012.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Moritani K, Kanemitsu Y, Shida D, Shitara
K, Mizusawa J, Katayama H, Hamaguchi T and Shimada Y: Colorectal
Cancer Study Group (CCSG) of Japan Clinical Oncology Group (JCOG).
A randomized controlled trial comparing primary tumour resection
plus chemotherapy with chemotherapy alone in incurable stage IV
colorectal cancer: JCOG1007 (iPACS study). Jpn J Clin Oncol.
50:89–93. 2020.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016.PubMed/NCBI View Article : Google Scholar
|
